Submitted by Anonymous (not verified) on 9 October 2023 - 11:55
Human medicines European public assessment report (EPAR): Lucentis, ranibizumab, Wet Macular Degeneration;Macular Edema;Diabetes Complications;Myopia, Degenerative, Date of authorisation: 22/01/2007, Revision: 43, Status: Authorised
Source: